ISDA

Entry Detail

PDB ID:

4ZYI

Keywords:

Title:

Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with cpd2

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2015-05-21

Release Date:

2015-07-29

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.67 Å

R-Value Free:

0.24

R-Value Work:

0.23

R-Value Observed:

0.23

Space Group:

P 61 2 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:E3 ubiquitin-protein ligase Mdm2
Chain IDs:A
Chain Length:96
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q00987 Pfam ID:PF02201 EC:2.3.2.27

Ligand Molecules

4TH

Primary Citation

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.

Holzer, P, Masuya, K, Furet, P, Kallen, J, Valat-Stachyra, T, Ferretti, S, Berghausen, J, Bouisset-Leonard, M, Buschmann, N, Pissot-Soldermann, C, Rynn, C, Ruetz, S, Stutz, S, Chene, P, Jeay, S, Gessier, F.Show

J.Med.Chem. 58 6348 6358 (2015)

PMID: 26181851 DOI: 10.1021/acs.jmedchem.5b00810

Abstact

As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview of the discovery of this new clinical p53:MDM2 inhibitor. The following aspects are addressed: mechanism of action, scientific rationale, binding mode, medicinal chemistry, pharmacokinetic and pharmacodynamic properties, and in vivo pharmacology/toxicology in preclinical species.

Legend

Protein

Chemical

Disease

Primary Citation of related structures